Ben is Xconomy's Deputy Biotechnology Editor. He is a seasoned business journalist that comes to Xconomy after a nine-year stint at The Deal, where he covered corporate transactions in industries ranging from biotech to auto parts and gaming. Most recently, Ben was The Deal’s senior healthcare writer, focusing on acquisitions, venture financings, IPOs, partnerships and industry trends in the pharmaceutical, biotech, diagnostics and med tech spaces. Ben wrote features on creative biotech financing models, analyses of middle market and large cap buyouts, spin-offs and restructurings, and enterprise pieces on legal issues such as pay-for-delay agreements and the Affordable Care Act. Before switching to the healthcare beat, Ben was The Deal's senior bankruptcy reporter, covering the restructurings of the Texas Rangers, Phoenix Coyotes, GM, Delphi, Trump Entertainment Resorts and Blockbuster, among others. Ben has a bachelor’s degree in English from Binghamton University.
There was biotech news up and down the East Coast this week. In Boston, all eyes were on the first biotech IPO of the year—and the sector let out a collective... Read more »
[Updated, 2/5/16, 7:06 am ET] Marc Tessier-Lavigne spent much of his professional life on the West Coast before becoming president of Rockefeller University in 2011. From that perch, the... Read more »
After a few years of explosive hype and no shortage of controversy, the gene editing system known as CRISPR-Cas9 has finally made its way to the public markets. This evening, Editas... Read more »
With three different ways of attacking troublesome drug-resistant bacteria in its portfolio, Spero Therapeutics has begun to resemble something of an antibiotics roll-up. And now it’s got another $30 million to... Read more »
Avalanche Biotechnologies went public during a renaissance for gene therapy, but it’s been searching for a way forward ever since a disappointing trial led to an executive overhaul. The Menlo Park,... Read more »
January is just about over, and for biotech investors, that’s a good thing. The Nasdaq Biotechnology Index (NASDAQ: IBB) has plummeted more than 22 percent in January. Thursday alone the... Read more »
2015 was a year of change for Blend Therapeutics, led by a new CEO, Drew Fromkin, who was hired in April to lead a different strategy for the Watertown, MA-based startup.... Read more »
It’s been a roller coaster few months for the community of caregivers and patients with Duchenne muscular dystrophy, a progressive and ultimately fatal genetic disease. One potential treatment from BioMarin Pharmaceutical... Read more »
OncoMed Pharmaceuticals has been adept at bringing in partners like GlaxoSmithKline and Celgene to help fund its cancer stem cell work. But the Redwood City, CA, company took a big hit... Read more »
Winter Storm Jonas is headed for the East Coast, and the panicked grocery shopping and traffic nightmares have already begun. It’s impacted biotech too, postponing what would have been one of... Read more »
There’s something going on in New York biotech.
The Big Apple has long been an afterthought in life sciences. Glitzy new biotech startups form seemingly every week in Boston and the... Read more »
Depression is a notoriously difficult disease to test new drugs against for a multitude of reasons. One reason is that a pervasive placebo effect tends to cloud the clinical trial data.... Read more »
It’s been a turbulent year for Zafgen, to say the least. Two patients died in a Phase 3 clinical trial of its leading drug candidate and, in December, the FDA halted... Read more »
Eleven Biotherapeutics started out with a plan to make a portfolio of custom-designed protein drugs for a range of diseases before it changed course and started focusing exclusively on eye drugs.... Read more »
A few years ago Acorda Therapeutics bought Civitas Therapeutics, a biotech about to go public, in a bid to branch out into Parkinson’s. Clearly, that wasn’t a one-off move; this morning,... Read more »
The FDA on Thursday rejected an experimental drug for Duchenne muscular dystrophy from BioMarin Pharmaceutical, a decision that doesn’t necessarily come as a surprise given the harsh criticism of the drug... Read more »
Publicly traded biotech stocks have been getting pounded during this year’s J.P. Morgan Healthcare Conference in San Francisco, but money is still flowing into privately held startups this week. The latest... Read more »
There’s always some last-minute dealmaking on the eve of the annual J.P. Morgan Healthcare Conference in San Francisco, and this year is no exception. Here are a few of the East... Read more »
Seattle’s Accelerator Corp. made its long-awaited splash in New York last week with its first Manhattan biotech startup, Petra Pharma. Now here comes Lodo Therapeutics, Accelerator’s second startup, right in... Read more »
March 31, 2016
© 2007-2016, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.